Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirofiban vs Placebo in Acute Ischemic Stroke (ADJUVANT-2)
NCT06373042Phase 3Not yet recruiting
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Tirofiban with Placebo (2 arms). Primary endpoint: Functional independence at 90 days. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06373042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373042.